Skip to Main Content

Paper Details

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China.
Front Cardiovasc Med
8
2022
Author NameAffiliation
Jiapeng LuNational Clinical Research Center for Cardiovascular Diseases, National Health Commission (NHC) Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Jiamin LiuNational Clinical Research Center for Cardiovascular Diseases, National Health Commission (NHC) Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Haibo ZhangNational Clinical Research Center for Cardiovascular Diseases, National Health Commission (NHC) Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Xi LiNational Clinical Research Center for Cardiovascular Diseases, National Health Commission (NHC) Key Laboratory of Clinical Research for Cardiovascular Medications, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
Xi LiCentral China Sub-center of the National Center for Cardiovascular Diseases
  • 1 - 5

Datasets